Intrapatient comparison of 2-deoxy-2-[F-18]fluoro-D-glucose with positron emissiontomography/computed tomography to Tc-99m fanolesomab (NeutroSpec) for localization of infection.
OBJECTIVE
This study evaluated the efficacy of 2-deoxy-2-[F-18]fluoro-D: -glucose (FDG) with positron emission tomography/computed tomography (PET/CT) in comparison with Tc-99m fanolesomab (NeutroSpec) for imaging infection.


METHODS
Twelve patients with possible infection were studied with both FDG-PET/CT and Tc-99m fanolesomab. One patient was studied twice for a total of 13 paired studies. The final determination of the presence or absence of infection and the site(s) of infection at the time of imaging was made by an infectious disease physician using culture results and other relevant information. The sensitivity, specificity, and accuracy were calculated for each imaging study on a per paired study basis and a per lesion basis. In addition, the quality of lesion depicted was compared between the two studies.


RESULTS
Three patients were determined not to have infection. Ten paired studies, in nine patients, were determined to have one or more sites of infection: seven had one site and three had two sites. On a per paired study basis the sensitivity, specificity, and accuracy of FDG-PET/CT were all 100%; for Tc-99m fanolesomab these parameters were 30, 100, and 46%, respectively (P < 0.01 for sensitivity and accuracy). On a per site basis the results for FDG-PET/CT were all 100% and for Tc-99m fanolesomab they were 23, 100, and 38% (P < 0.01 for sensitivity and accuracy). In the three sites of infection shown by both studies, FDG-PET/CT was judged to be superior in spatial resolution and anatomic localization compared to Tc-99m fanolesomab in all three sites.


CONCLUSIONS
FDG-PET/CT is superior to Tc-99m fanolesomab for detecting and localizing sites of infection.
Klingensmith
William C
WC
Hewit Biomolecular Imaging Center, Department of Radiology, Porter Hospital, Denver, CO 80210, USA. bill.klingensmith@mac.com
Perlman
Daniel
D
Baum
Kenneth
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007239:Infections / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D049268:Positron-Emission Tomography / Q000379:methods / Q000706:statistics & numerical data; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
D000911:Antibodies, Monoclonal; D005462:Fluorine Radioisotopes; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C414128:techneticum TC-99M fanolesomab